TY - JOUR
T1 - Differential effects of heart rate reduction by atenolol or ivabradine on peripheral endothelial function in type 2 diabetic patients
AU - Nerla, Roberto
AU - Di Franco, Antonino
AU - Milo, Maria
AU - Pitocco, Dario
AU - Zaccardi, Francesco
AU - Tarzia, Pierpaolo
AU - Sarullo, Filippo Maria
AU - Villano, Angelo
AU - Russo, Giulio
AU - Stazi, Alessandra
AU - Ghirlanda, Giovanni
AU - Lanza, Gaetano Antonio
AU - Crea, Filippo
PY - 2012/12
Y1 - 2012/12
N2 - Objective: To assess whether reduction of heart rate (HR) has beneficial effects on endothelial function in patients with type 2 diabetes mellitus (T2DM). Design: Randomised, double-blind, placebo-controlled study. Setting: University hospital. Patients: 66 T2DM patients without overt cardiovascular disease. Interventions: Patients were randomised to receive for 4 weeks, in addition to their standard therapy, one of the following treatments: atenolol (25 mg twice daily), ivabradine (5 mg twice daily) or placebo (1 tablet twice daily). Main outcome measures: Systemic endothelial function, assessed by flow-mediated dilation (FMD); endothelium-independent vasodilation, assessed by nitrate-mediated dilation (NMD); cardiac autonomic function, assessed by HR variability (HRV). Results: 61 patients completed the study (19, 22 and 20 patients in atenolol, ivabradine and placebo groups, respectively). Compared with baseline, HR was similarly reduced by atenolol (87±13 vs 69±9 bpm) and ivabradine (86±12 to 71±9 bpm), but not by placebo (82±10 vs 81±9 bpm) (p
AB - Objective: To assess whether reduction of heart rate (HR) has beneficial effects on endothelial function in patients with type 2 diabetes mellitus (T2DM). Design: Randomised, double-blind, placebo-controlled study. Setting: University hospital. Patients: 66 T2DM patients without overt cardiovascular disease. Interventions: Patients were randomised to receive for 4 weeks, in addition to their standard therapy, one of the following treatments: atenolol (25 mg twice daily), ivabradine (5 mg twice daily) or placebo (1 tablet twice daily). Main outcome measures: Systemic endothelial function, assessed by flow-mediated dilation (FMD); endothelium-independent vasodilation, assessed by nitrate-mediated dilation (NMD); cardiac autonomic function, assessed by HR variability (HRV). Results: 61 patients completed the study (19, 22 and 20 patients in atenolol, ivabradine and placebo groups, respectively). Compared with baseline, HR was similarly reduced by atenolol (87±13 vs 69±9 bpm) and ivabradine (86±12 to 71±9 bpm), but not by placebo (82±10 vs 81±9 bpm) (p
UR - http://www.scopus.com/inward/record.url?scp=84870416330&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84870416330&partnerID=8YFLogxK
U2 - 10.1136/heartjnl-2012-302795
DO - 10.1136/heartjnl-2012-302795
M3 - Article
C2 - 23086971
AN - SCOPUS:84870416330
VL - 98
SP - 1812
EP - 1816
JO - Heart
JF - Heart
SN - 1355-6037
IS - 24
ER -